Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Report: Russian military pressuring students to work as drone pilots - 22025 Arctic League telethon raises more than $39k
- 3How did I get my own unique set of fingerprints?
- 4Exposure to neighborhood violence leads some Denver teens to use tobacco and alcohol earlier, new study shows
- 5Exemplary Fragrances: A Manual for Notorious Scents
- Brazil's agricultural research agency gets cannabis research greenlight
- The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
- The Response to Independence from the rat race: Methodologies for Creating Financial momentum
- 7 Methods for further developing Rest Quality
- Vote in favor of your Number one Sort of Cap
- From Lounge chair to Money: Online Positions That Will Change Your Profession
- Step by step instructions to Streamline Your Dozing Involvement in a Savvy Bed
- French ship crosses Strait of Hormuz in first Western European transit during Iran war
- Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
